WHO ICTRP trial
Clonazepam in patients with ARID1B-related intellectual disability
ISRCTN11225608 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN11225608 |
|---|---|
| Public title | Clonazepam in patients with ARID1B-related intellectual disability |
| Scientific title | Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures in patients with ARID1B-related intellectual disability |
| Primary sponsor | Centre for Human Drug Research |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | Netherlands |
| Conditions | ARID1B-related intellectual disability Mental and Behavioural Disorders |
| Interventions | Part A (open-label study) • Clonazepam (Rivotril) droplets for oral use, solution 2.5 mg/ml, dissolved in lemonade. Dose: 0.5 mg or 1 mg, both administered to 50% of subjects. Part B (randomised cross-over study) • Active medication… |
| Registration date | Jul 9, 2022 |
| Target size | 40 |
| Secondary IDs | 2019-003558-98;Nil known;CHDR1939 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: